/
© 2026 RiffOn. All rights reserved.

Get your free personalized podcast brief

We scan new podcasts and send you the top 5 insights daily.

  1. Research To Practice | Oncology Videos
  2. Prostate Cancer — An Interview with Prof Karim Fizazi (Companion Faculty Lecture)
Prostate Cancer — An Interview with Prof Karim Fizazi (Companion Faculty Lecture)

Prostate Cancer — An Interview with Prof Karim Fizazi (Companion Faculty Lecture)

Research To Practice | Oncology Videos · Oct 23, 2026

ASCO 2026 prostate cancer: ARPI intensification debated; PSMA radioligands and PARP/AKT precision strategies show strong rPFS gains.

A-DREAM: 40% of exceptional responders treatment-free at 18 months

Fizazi reports the phase 2 A-DREAM trial, where patients with dramatic responses after 18–24 months of ADT and at least a year of an AR pathway inhibitor stopped treatment. About 40% were treatment-free and eugonadal at 18 months, with a median roughly two years before progression. Formal phase 3 testing is ongoing.

Prostate Cancer — An Interview with Prof Karim Fizazi (Companion Faculty Lecture) thumbnail

Prostate Cancer — An Interview with Prof Karim Fizazi (Companion Faculty Lecture)

Research To Practice | Oncology Videos·a month ago

Neoadjuvant ADT hides PSA, blocking adjuvant decisions

Fizazi criticizes PROTEASE's control arm because it was not surgery alone; both arms received neoadjuvant ADT, which drives postoperative PSA to zero. That prevents clinicians from using PSA to trigger adjuvant radiation or intensification, a key limitation for translating the trial into practice. He calls this a design criticism.

Prostate Cancer — An Interview with Prof Karim Fizazi (Companion Faculty Lecture) thumbnail

Prostate Cancer — An Interview with Prof Karim Fizazi (Companion Faculty Lecture)

Research To Practice | Oncology Videos·a month ago

TALAPRO-3 benefit extends beyond BRCA2 to CDK12

In TALAPRO-3, adding talazoparib to ADT plus enzalutamide in de novo metastatic hormone-sensitive prostate cancer with DNA repair alterations sharply improved radiographic progression-free survival. Fizazi says the benefit appears across alterations, including BRCA2 and biallelic CDK12, though gene-by-gene homework remains. He also sees an overall survival signal, but final analysis is pending.

Prostate Cancer — An Interview with Prof Karim Fizazi (Companion Faculty Lecture) thumbnail

Prostate Cancer — An Interview with Prof Karim Fizazi (Companion Faculty Lecture)

Research To Practice | Oncology Videos·a month ago

PSMA PET endpoint amendment turned PROTEASE trial positive

Fizazi says PROTEASE was positive for metastasis-free survival only after investigators amended the protocol to include PSMA PET; the original conventional-imaging endpoint had a p-value above 0.05. That split interpretation—positive by amended endpoint, not by original—fuels debate about whether to intensify high-risk localized disease. He notes opinions remain divided among clinicians.

Prostate Cancer — An Interview with Prof Karim Fizazi (Companion Faculty Lecture) thumbnail

Prostate Cancer — An Interview with Prof Karim Fizazi (Companion Faculty Lecture)

Research To Practice | Oncology Videos·a month ago

PSMAfore's missing OS benefit reflects heavy crossover

Fizazi notes PSMAfore improved radiographic progression-free survival with a hazard ratio of 0.5, yet showed no overall survival benefit because most control patients crossed over to lutetium PSMA, often progressing within six months. He frames the comparison as immediate versus deferred radioligand therapy. Quality-of-life and symptomatic progression still favored treatment.

Prostate Cancer — An Interview with Prof Karim Fizazi (Companion Faculty Lecture) thumbnail

Prostate Cancer — An Interview with Prof Karim Fizazi (Companion Faculty Lecture)

Research To Practice | Oncology Videos·a month ago

CYP11 inhibitor blocks all steroids to target mutant AR

Fizazi explains that under hormonal pressure, androgen receptor mutations can let progesterone, prednisone, or estrogens stimulate prostate cancer. Opevesostat blocks CYP11, the first enzyme downstream of cholesterol, suppressing all steroid hormones; patients need glucocorticoid and mineralocorticoid replacement, and OMAR trials are testing it before and after docetaxel.

Prostate Cancer — An Interview with Prof Karim Fizazi (Companion Faculty Lecture) thumbnail

Prostate Cancer — An Interview with Prof Karim Fizazi (Companion Faculty Lecture)

Research To Practice | Oncology Videos·a month ago